Navigation Links
TriLink BioTechnologies, Inc. Announces License Agreement with Lucigen Corporation
Date:7/28/2011

SAN DIEGO, July 28, 2011 /PRNewswire/ -- TriLink BioTechnologies, Inc. (TriLink) and Lucigen Corporation (Lucigen) announced today that the two companies have signed a licensing agreement for the use of TriLink's CleanAmp™ dNTPs in Lucigen's new Taq98™ Hot Start 2X MasterMix.

TriLink's CleanAmp™ dNTPs are an innovative approach to Hot Start PCR. By simply replacing the standard dNTPs in a PCR assay with CleanAmp™ dNTPs, a Hot Start reaction can be achieved. This universal approach to high stringency PCR offers a cost effective method to vastly reduce mis-priming, primer dimer formation and other common deleterious off-target effects in PCR.

Lucigen has offered its popular EconoTaq® DNA Polymerase and EconoTaq® PLUS 2X Master Mixes for several years, garnering a reputation for robustness and cost effectiveness. As part of their mission to simplify genomic research, Lucigen has developed the new Taq98™ Hot Start 2X Master Mix for customers seeking to amplify difficult DNA templates, including targets with >70% GC content. The product is expected to be available for sale in mid-August.  

"We believe Taq98™ represents a great combination of performance, ease-of-use, and value for the customer. The addition of the Hot Start feature has significantly increased the market for this product," stated Jeff Williams, Lucigen President.

"We have found that CleanAmp™ dNTPs improve the performance of a number of thermostable DNA polymerases, allowing for simple conversion of any assay to a Hot Start version. We are pleased to find synergy between TriLink's CleanAmp™ dNTPs and Lucigen's amplification product line," said Dr. Natasha Paul, TriLink Scientific Investigator.

"CleanAmp™ dNTPs are a unique molecular biology tool. As an alternative approach to Hot Start PCR, CleanAmp™ opens new doors for innovation. We are very pleased to be able to work with Lucigen to develop novel products with our combined technologies," commented TriLink CEO, Dr. Richard Hogrefe.

About TriLink

TriLink manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp™ PCR products for the research, diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR compliant cGMP production facilities are offered. TriLink's solutions help advance drug discovery and biomedical research. Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 80 scientists and other professionals. For more information about the firm and products, call 858-546-0004, email info@trilinkbiotech.com, or visit our web site at www.trilinkbiotech.com.

About Lucigen

Located in Middleton, WI, Lucigen delivers advanced molecular biology products and services to life scientists by inventing solutions to the most difficult problems in DNA cloning, amplification, and protein expression. With a focus on simplifying genomic research, Lucigen offers a wide selection of cloning kits, competent cells, and enzymes that enable scientists to quickly and easily complete even the most challenging molecular biology experiments. For more information about the firm and products, call 888-575-9695, email Lucigen@lucigen.com, or visit our website at www.lucigen.com.


'/>"/>
SOURCE TriLink BioTechnologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES, a Benefit Concert to Help Alleviate Hunger in San Diego County
2. TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services
3. TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)
4. TriLink BioTechnologies to Sponsor Take Me Out to the Ballgame, a SAY San Diego Event Benefiting San Diego Families in Need
5. TriLink BioTechnologies Launches CleanAmp™ 7-deaza-dGTP for GC-rich Target Amplification
6. TriLink Awarded SBIR Phase I Grant: Thermally Activatable Probes and Cofactors for Hot Start Ligase Chain Reaction
7. TriLink Enters Into Distribution Agreement With TATAA Biocenter
8. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
9. Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc.
10. Glycos Biotechnologies, Inc. Selected to Present at Alternative Energy Innovations 2009
11. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... Parallel6™ , the leader in ... today that they were named one of the 2017 Top 10 eClinical Trial ... in the pharmaceutical industry. , “We take pride in honoring Parallel6 as one of ...
(Date:4/20/2017)... N.J. and PETACH TIKVAH, Israel ... BCLI), a leading developer of adult stem cell technologies for ... Executive Officer, will present at the Alliance for Regenerative Medicine,s ... Day on Thursday, April 27, 2017 at 09:40 EDT in ... Ralph Kern , MD, MHSc, Chief Medical Officer & ...
(Date:4/19/2017)... ... ... A number of new instruments have recently emerged to accommodate different applications ... and Cell Analysis Education Webinar Series , will focus on advances in the Invitrogen™ ... applications. , Many flow cytometers have unique capabilities and the Attune NxT Flow ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion ... to Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , ... patient clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
Breaking Biology News(10 mins):